N2126
Neostigmine methyl sulfate
Synonym(s):
3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-trimethylanilinium methyl sulfate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Pack Size | SKU | Availability | Price |
|---|
About This Item
Empirical Formula (Hill Notation):
C13H22N2O6S
CAS Number:
Molecular Weight:
334.39
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
200-109-5
MDL number:
Form:
solid
Quality level:
Pricing and availability is not currently available.
Biochem/physiol Actions
Reversible inhibitor of acetylcholinesterase that is similar to eserine, but does not cross the blood-brain barrier.
Reversible inhibitor of acetylcholinesterase; does not cross the blood-brain barrier.
1 of 1
This Item | |||
|---|---|---|---|
| form solid | form powder | form - | form - |
| Quality Level 100 | Quality Level 100 | Quality Level - | Quality Level - |
| storage temp. −20°C | storage temp. - | storage temp. - | storage temp. - |
| Gene Information human ... ACHE(43) | Gene Information human ... ACHE(43) | Gene Information human ... ACHE(43) | Gene Information human ... ACHE(43) |
Still not finding the right product?
Explore all of our products under Neostigmine methyl sulfate
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
C T Sadashiva et al.
Bioorganic & medicinal chemistry letters, 16(15), 3932-3936 (2006-06-01)
The cholinergic hypothesis of Alzheimer's disease (AD) has spurred the development of numerous structural classes of compounds with different pharmacological profile aimed at increasing central cholinergic neurotransmission. Thus proving a symptomatic treatment for this disease are cholinomimetics with the pharmacological
Michael Benatar et al.
The Cochrane database of systematic reviews, 12, CD005081-CD005081 (2012-12-14)
Approximately 50% of people with myasthenia gravis present with purely ocular symptoms, so called ocular myasthenia. Of these between 50% to 60% develop generalized disease, most within two years. Their management is controversial. This is an update of a review
Qian-Sheng Yu et al.
Bioorganic & medicinal chemistry, 18(13), 4687-4693 (2010-07-16)
The N-monophenylcarbamate analogues of neostigmine methyl sulfate (6) and pyridostigmine bromide (8) together with their precursors (5), (7), and the N(1)-methylammonium analogues of (-)-phenserine (12), (-)-tolserine (14), (-)-cymserine (16) and (-)-phenethylcymserine (18) were synthesized to produce long-acting peripheral inhibitors of
Global Trade Item Number
| SKU | GTIN |
|---|---|
| N2126-500MG | 04061834110125 |
| N2126-5G | 04061834110132 |
| N2126-1G | 04061835557950 |